C4 Therapeutics (CCCC) Amortization of Deferred Charges (2019 - 2026)

C4 Therapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 12.61% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 4.08% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, changed 0.2% from the prior year.
• Amortization of Deferred Charges advanced to $1.4 million in Q1 2026 per CCCC's latest filing, from $1.4 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.7 million in Q2 2022 and bottomed at $1.2 million in Q1 2022.
• The 5-year median for Amortization of Deferred Charges is $1.6 million (2023), against an average of $1.6 million.
• Across the five-year window, Amortization of Deferred Charges soared 421.71% in 2022 and slipped 12.61% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.5 million in 2022, then increased by 4.06% to $1.6 million in 2023, then gained by 4.35% to $1.6 million in 2024, then slipped by 12.39% to $1.4 million in 2025, then rose by 0.84% to $1.4 million in 2026.
• Per Business Quant, the three latest CCCC Amortization of Deferred Charges figures stand at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.7 million (Q3 2025).